Piper Jaffray analyst Matt O'Brien suspended his rating and price target on MiMedx Group after the company disclosed that the Department of Justice is reviewing matters in parallel with an SEC investigation. The analyst, up until tonight, had an Overweight rating on MiMedx with an $18 price target. The stock closed the trading day down 15c to $7.12. "We have been standing by MiMedx in recent months despite numerous short selling reports on the company," O'Brien tells investors in a research note. He says, however, that the Department of Justice review, which is added to an Audit Committee and SEC investigation regarding the company's sales and distribution practices, is "simply too much for us to digest at the moment."